Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04339218
Recruiting Phase 3

Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

NCT04339218 · tracked via the Priya Life Science France tracker
Sponsor
Institut Bergonié
Phase
Phase 3
Started
2020-08-28
Last updated
2026-01-30

Condition(s) studied

Lung AdenocarcinomaCryotherapy Effect

Investigational drug(s) / intervention(s)

CryoablationPembrolizumab →Pemetrexed →Carboplatin →

Cryoablation: Cryoablation will be performed by a specialized radiologist, percutaneously, ie "through the skin". The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold. The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly.

Pembrolizumab: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.

Pemetrexed: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.

Carboplatin: Carboplatin will be prescribed and administered at the dose recommended by market authorization.

Study summary

This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients.

This is a multicenter, prospective, open-labeled, 2-arm comparative randomized (1:1) phase III trial.

Patients will be randomized with a 1:1 ratio into:

* Arm A (experimental arm): cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
* Arm B (standard arm): pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.

Pembrolizumab and pemetrexed-carboplatin will be prescribed and administered at the dose recommended by market authorization.

Cryoablation treatment should be performed within 6 weeks after the first administration of pembrolizumab. No treatment switching permitted.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically or cytologically confirmed non-small lung adenocarcinoma. 2. Metastatic disease. 3. Treatment with pembrolizumab in combination with pemetrexed-carboplatin as per market authorization. 4. At least two target lesions (RECIST1.1), measurable with CT or MRI : 1. One target lesion that is amenable for accurate repeated measurements, 2. One target lesion (15-40 mm) that is amenable for cryoablation treatment including lung, kidney, adrenal, soft tissue and lytic bone lesions. Liver and sclerotic bone lesions are not allowed to be treated by cryoablation. 5. Age ≥ 18. 6. Performance status ≤ 2. 7. Women of childbearing potential must have a negative serum pregnancy test prior to registration. 8. Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia) 9. Patients with a social security in compliance with the French law (Loi Jardé). 10. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 11. Voluntarily signed and dated written informed consents prior to any study specific procedure. Exclusion Criteria: 1. Squamous cell tumors and other than adenocarcinoma. 2. Prior systemic treatment for advanced non-small cell lung cancer (except adjuvant therapy after complete resection). 3. Current or prior use of immunosuppressive medication including any use of oral glucocorticoids, within 21 days before the first dose of pembrolizumab. 4. Known contra-indication and/or hypersensitivity to PD1/PD-L1 antagonist and/or cytotoxic therapy. 5. Known contra-indication to cryoablation. 6. Abnormal coagulation contraindicating biopsy. 7. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma or incidentally discovered good prognosis prostate cancer (T stage \< pT3 and Gleason ≤ 7). 8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. 9. Subjects who participated in an investigational drug or device study within 28 days prior to study entry. 10. Known infection with HIV, hepatitis B, or hepatitis C. 11. Females who are pregnant or breast-feeding. 12. Men or women refusing contraception. 13. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. 14. Previous enrolment in the present study. 15. Individuals deprived of liberty or placed under legal guardianship.

Primary outcome measure(s)

  • 1-year overall survival rate — 1 year
    Overall survival (OS) is defined as the time interval between the date of randomization and the date of death (from any cause). Patients alive will be censored at the date of last follow-up or last patient contact. One-year OS rates will be compared between arms.

Trial sites (1)

FacilityCityRegionStatus
Institut Bergonié Bordeaux Gironde Recruiting

On this site

📄 Keytruda (pembrolizumab) drug profile →

More Institut Bergonié trials in France

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) Active, not recruiting
High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study Recruiting
National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group Recruiting
Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer. Active, not recruiting
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer Recruiting

Other trials for the same condition

National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04339218 on ClinicalTrials.gov ↗ ← All trials in France